The quarterly journal of nuclear medicine and molecular imaging : official publication of the Italian Association of Nuclear Medicine (AIMN) [and] the International Association of Radiopharmacology (IAR), [and] Section of the Society of Radiopharmaceutical Chemistry and Biology
-
Q J Nucl Med Mol Imaging · Mar 2008
FDG-PET in the detection of bone marrow disease in Hodgkin's disease and aggressive non-Hodgkin's lymphoma and its impact on clinical management.
Identification of bone marrow disease (BMD) is a crucial step in the diagnostic work-up of patients with lymphoma. In lymphoma staging, bone marrow biopsy (BMb) is considered as the gold standard, despite its limitations. The aim of this study was to compare the usefulness of 2-deoxy-2-[(18)F]fluoro-D-glucose positron emission tomography (FDG-PET) vs BMb in the detection of BMD in patients with Hodgkin's disease (HL) or aggressive non-Hodgkin's lymphoma (NHL) and its impact on therapy. ⋯ Our study demonstrates that BMb and FDG-PET are complementary in the evaluation of BMD. FDG-PET improves the sensitivity of BMb, especially in the presence of focal BMD. Performing FDG-PET before BMb is advised for optimal biopsy site targeting.
-
Q J Nucl Med Mol Imaging · Dec 2007
S-factor calculations for mouse models using Monte-Carlo simulations.
Targeted radionuclide therapy applications require the use of small animals for preclinical experiments. Accurate dose estimation is needed in such animals to explore and analyze the toxicity of injected radiopharmaceuticals. We developed two numerical models to allow for a more accurate mouse dosimetry. ⋯ The voxel-based models represent more realistic anatomic approach. The rapid advancement of computer science and new features added to Monte-Carlo codes permit considerable reduction of computational run time. Cross-doses should not be neglected when medium to high energy beta emitters are being used for preclinical experiments on mice.
-
Q J Nucl Med Mol Imaging · Sep 2007
Comparative StudyTwo-dimensional vs three-dimensional imaging in whole body oncologic PET/CT: a Discovery-STE phantom and patient study.
To evaluate the performance of the positron emission tomography (PET)/computed tomography (CT) Discovery-STE (D-STE) scanner for lesion detectability in two-dimensional (2D) and three-dimensional (3D) acquisition. ⋯ In oncological applications, the D-STE system demonstrated good performance in 2D and 3D acquisition, while 3D exhibited better image quality, data accuracy and consistency of lesion detectability, resulting in shorter scan times and higher patient throughput.
-
Positron emission tomography (PET) has become an integral part of the management of patients with cancer as well as some cardiac and neurological diseases. 18F-fluorodeoxyglucose (FDG) PET is commonly used to stage cancer patients after initial diagnosis, but is increasingly used at other points in the patient's management, including the assessment of treatment response and detecting recurrent disease. In common with most imaging techniques there are pitfalls in interpretation of PET and PET/computed tomography (CT) studies. Many potential pitfalls and artefacts have previously been described with 18F-FDG PET imaging, but more continue to become apparent as worldwide experience increases. ⋯ It is important that referring clinicians, PET/CT interpreters and imaging technologists/radiographers are aware of potential pitfalls so that their impact is minimised and that the image data are acquired and interpreted in the most accurate manner. With careful patient preparation, attention to detail and adequate training, the se artefacts and pitfalls may be minimised allowing this powerful hybrid imaging technique to realise it's potential. This paper attempts to describe some of the common pitfalls and artefacts and how they can be avoided or appropriately interpreted.